摘要
制备了丙酸倍氯米松醋酸乙酯溶剂化物(1)及其微粉,用以制备丙酸倍氯米松混悬型气雾剂。分别对1及微粉的理化性质和制备的气雾剂的行为进行了考察。X衍射、热重分析及红外光谱测定结果证实醋酸乙酯以结合形式存在于1中。EtOAc/1结合百分比约为9%。采用微粉化工艺制得3批样品的粒径分别为1.68±0.62、2.34±1.63、2.44±0.56μm。且微粉化过程无结合溶剂损失及晶型转化发生。外冲程实验表明,该气雾剂在肺深部的沉积达45%以上。
Beclomethasone dipropionate ethyl acetate solvate (1), and its micronized powder were prepared. X-ray diffraction, DTA and IR spectrum showed that ethyl acetate existed in combined form up to about 9% in solvate crystal lattice in both crystalline solvate and micronized powder. Micronized powder had particle sizes of 1.68±0.62, 2.34±1.63 and 2.44±0.56 μm. No loss of combined solvent or crystal form transformation were observed during micronization. In vitro performance test implied that MDIs with potency of 50 μg/dose prepared with above micronized solvates had drug deposition in deep lung over 45%.
出处
《中国医药工业杂志》
CAS
CSCD
北大核心
1998年第1期16-18,共3页
Chinese Journal of Pharmaceuticals